22 results about "High sugar diet" patented technology

The invention relates to application of fermentation lactobacillus mucus LFPerfectuus001 in preparation of a product for improving metabolic syndrome caused by high-fat and high-sugar diet, and belongs to the technical field of microorganisms. The invention provides application of fermented lactobacillus mucus LFPerfecus001 in preparation of a product for improving metabolic syndrome, the fermented lactobacillus mucus LFPerfecus001 is preserved in Guangdong Microbial Culture Collection Center on April 13, 2022, and the preservation number is GDMCC No: 62335. The invention further provides a preparation method of the fermented lactobacillus mucus LFPerfecus001. Animal experiments report that the fermented lactobacillus mucus LFPerfectus001 has the effects of reducing fat, increasing muscle, improving obesity, hyperglycemia, insulin resistance, dyslipidemia, hyperuricemia and fatty liver for the first time, and can well improve metabolic syndrome caused by high fat and high glucose.

The invention discloses a construction method of a metabolism-related fatty liver cancer (MAFLD liver cancer) mouse model, and relates to the technical field of biology. The specific construction method comprises the following steps: feeding a 7-9-week-old mouse with a high-fat and high-sugar diet for 24 weeks, inducing the mouse to form fatty liver, and causing metabolic dysfunction; injecting carbon tetrachloride into the abdominal cavity of the mouse once a week while feeding the mouse with the high-fat and high-sugar diet, and inducing the liver of the mouse to form liver cancer continuously for 24 weeks, so as to construct the MAFLD liver cancer mouse. The mouse liver constructed by the method has metabolic dysfunction, fatty liver and liver cancer lesions, and has extremely high application value in research and development of drugs for researching MAFLD liver cancer pathogenesis and fatty liver related liver cancer in the future.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

The invention provides application of nitraria tangutorum bobr extract in preparation of products for regulating glycolipid metabolism disorder, and relates to the technical field of plant extract application. The nitraria macrocarpa extract is a composition rich in alkaloid and flavonoid compounds, wherein the sum of the content of total alkaloid and the content of total flavonoids is not lower than 85% of the total weight of the extract. The extract is prepared through the processes of fresh fruit juicing, alcohol precipitation impurity removal and AB-8 macroporous resin gradient elution. Experiments show that the extract can significantly reduce fasting blood glucose of type 2 diabetes mice induced by high-fat and high-sugar diet combined with STZ, improve sugar tolerance and insulin resistance, and synchronously regulate the blood fat level, and shows an excellent glucose and lipid metabolism synergistic improvement effect. The extract disclosed by the invention provides a choice for developing a safe and effective glycolipid metabolism regulator.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

The present invention relates to the field of biomedicine, and specifically provides an application of a selective TNFR1 antagonist peptide SN61‑4G in the treatment of non-alcoholic fatty liver disease. The selective TNFR1 antagonist peptide SN61‑4G has an amino acid sequence as shown in SEQ ID NO: 1. The present invention preliminarily verified its selective binding to TNFR1 and in vitro anti-inflammatory activity through in vitro experiments. The results showed that SN61‑4G may exhibit good anti-inflammatory activity by selectively binding to TNFR1 and inhibiting the interaction between TNF‑α and TNFR1. The present invention applies it to a mouse non-alcoholic fatty liver disease model induced by a high-fat and high-sugar diet (HFD), which is of great significance for the development of therapeutic drugs for non-alcoholic fatty liver disease.

The invention discloses an application of a flavonoid compound or a salt thereof in preparation of a medicine for preventing and / or treating fatty liver diseases. The flavonoid compound is a compound as shown in a formula I which is described in the specification. The nuezhenide can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases. In a free fatty acid (FFA)-induced THLE2 hepatocyte fatty degenerative cell model, the ligustroside remarkably reduces the content of TG in cells. Meanwhile, on metabolism-related fatty liver disease model mice induced by high-fat and high-sugar diet, the TG content of animal livers and the ALT activity of serum are reduced, and glycometabolism is remarkably improved. Therefore, the nuezhenide can be used for preparing the medicines and other products for preventing and treating the metabolism-related fatty liver diseases.

The present invention relates to the technical field of food processing, and particularly to a compound fermented cereal formula food and its application that can be used for blood sugar control, fat reduction and weight loss. The compound fermented cereal prepared by the present invention can effectively inhibit the activities of α-amylase and α-glucosidase, control fasting blood glucose and dyslipidemia; it can also promote the growth of the intestinal probiotic Akkermansia muciniphila (AKK bacterium), regulate the F / B value, effectively reduce body weight and abdominal fat, reduce the level of blood uric acid, improve liver function; alleviate the damaging effect of diabetes and high-fat and high-sugar diet patterns on the pancreas; and has the advantages of wide sources of preparation raw materials, low cost, safety and high efficiency. Further, the compounding of the compound fermented cereal and chlorogenic acid in the present invention can significantly improve the inhibitory activities against α-amylase and α-glucosidase, especially the inhibitory activity against α-glucosidase, which can be increased by up to 1.7 times compared with using chlorogenic acid alone.

The invention belongs to the technical field of resource development of non-medicinal parts of traditional Chinese medicines, and provides a bupleurum leaf extract, a preparation method thereof and application of the bupleurum leaf extract in preparation of medicines for preventing and treating metabolic syndromes. The extract comprises the following components in percentage by weight: 233.68 + / -20.27 mg / g of total polysaccharide, 62.41 + / -0.61 mg / g of total flavone, 48.40 + / -2.96 mg / g of total phenol, 0.87 + / -0.055% of radix bupleuri total saponin, 0.17 + / -0.006% of saikoside A, 0.22 + / -0.006% of saikoside B1, 0.05 + / -0.037% of saikoside C and 0.43 + / -0.006% of saikoside D. According to the present invention, the traditional Chinese medicine composition can significantly reduce body weight increase caused by high-fat and high-sugar diet, reduce blood fat, fasting blood glucose and blood uric acid level, improve body metabolic disorder induced by high-fat and high-sugar diet, has a callback effect on various organ lesions, has a regulation effect on complications such as diabetic retinopathy, and can be used as a functional product for preventing and treating metabolic syndrome.

The invention belongs to the technical field of biological medicines, and relates to a traditional Chinese medicine micromolecule composition and application thereof in preparation of medicines for treating metabolism-related fatty liver diseases. Through combined use of two or more of naringin, sophoriol, 8-isopentenyl naringenin and butene-7-O-beta-D-glucopyranoside, especially combined use of the four components, weight gain of MAFLD mice induced by high-fat diet / high-fat and high-sugar diet can be significantly reduced, lipid accumulation in the liver is reduced, and the weight loss of the mice is reduced. The insulin resistance is relieved, and the hepatocyte injury is improved. The composition can improve blood biochemical indexes related to lipid metabolism, relieve oxidative stress, increase fat consumption and improve a metabolic mode, and the effect is superior to that of a western medicine rosuvastatin positive control group and that of a western medicine rosuvastatin single use group.

The invention discloses a composite plant source and functional sugar powder composition for assisting in reducing blood sugar. The composition is prepared from the following raw materials in parts by weight: 5 to 10 parts of stevia rebaudiana polyphenol, 8 to 15 parts of angelica keiskei extract, 10 to 20 parts of aronia melanocarpa fruit extract, 15 to 25 parts of lithocarpus litseifolius extract, 3 to 8 parts of tagatose, 15 to 20 parts of oat beta-glucan, 20 to 30 parts of resistant dextrin, 2 to 5 parts of L-arabinose, 50 to 100 parts of a drying aid, 1 to 3 parts of a flow aid and 2 to 5 parts of a stabilizer. The powder is prepared through targeted extraction process optimization (55% ethanol aqueous solution extraction of stevia rebaudiana polyphenol, ultrasonic-assisted water extraction of angelica keiskei, acidic ethanol extraction of aronia melanocarpa fruits and composite enzymolysis-membrane separation of lithocarpus litseifolius) and low-temperature spray drying, and the retention rate of active ingredients is greater than or equal to 92%; experiments show that the powder can enable the blood glucose reduction amplitude of high-glucose diet mice to reach 38%-46% within 2 h after meal, the dissolution speed is smaller than or equal to 30 s, and the powder is free of gastrointestinal tract side effects and suitable for being brewed and drunk by people with hyperglycemia or added into food to serve as a health care product for assisting in reducing blood glucose.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a purified flavonoid from Sophora flavescens, its preparation method, and its application. Using Sophora flavescens as raw material, this invention extracts and separates purified flavonoid KSF50, and uses liquid chromatography-mass spectrometry (LC-MS / MS) to analyze and identify its components, determining its main functional groups and composition. The purified flavonoid from Sophora flavescens mainly contains the following six flavonoid components: daidzein, gentiopicrin, matrine O, trifolin stigmosiderin, matrine, and sophoridine. Furthermore, based on a high-sugar diet-induced *C. elegans* model and a high-sugar-induced 3T3-L1 preadipocyte model, this invention provides evidence that Sophora flavescens flavonoids can delay the aging of *C. elegans* by regulating lipid metabolism disorders, providing a theoretical basis for its application in medicine, cosmetics, and health functional foods.

The invention discloses application of dendrobine combined with lactobacillus paracasei, and particularly relates to application of dendrobine combined with lactobacillus paracasei in preparation of products for preventing and / or relieving learning and memory ability damage induced by high-sugar diet. Experiments prove that the combination of the dendrobine and the lactobacillus paracasei increases the variety diversity of intestinal flora, improves the glucose and lipid metabolism disorder of rats induced by high glucose, improves the abnormal blood fat and blood glucose, can prevent and / or improve the influence of the high glucose on the learning and memory ability of the rats, and has a good synergistic effect compared with the single use of the dendrobine or the lactobacillus paracasei. The combined use of dendrobine and lactobacillus paracasei also avoids the problem that the influence effect on learning and memory ability is not obvious when the dendrobine and lactobacillus paracasei are independently used, and the dendrobine and lactobacillus paracasei composition is effective and safe and has very high clinical application value.

This invention provides stevia extract and its applications. Specifically, the extract is obtained by extracting, concentrating, and fermenting stevia raw materials. Applications include the use of stevia extract in the preparation of formulations and / or foods that improve lipid metabolism, protect liver tissue, inhibit weight gain and / or blood glucose elevation caused by high-fat, high-sugar diets, reduce serum and / or liver TG and / or TC levels, inhibit HDL elevation and / or LDL reduction caused by high-fat, high-sugar diets, reduce FFA levels and / or AI index, improve oxidative stress caused by high-fat, high-sugar diets, inhibit colon shortening caused by high-fat, high-sugar diets, improve intestinal digestion and absorption capacity, and improve intestinal microbiota composition. This provides a new theoretical basis for using stevia extract to improve lipid metabolism disorders caused by high-fat diets, and also offers new ideas for the high-value utilization of natural agricultural waste, significantly expanding the application field of stevia and further exploring its physiological efficacy.

The application discloses a preparation method of a degraded polysaccharide of Gracilaria lemaneiformis capable of regulating short-chain fatty acid level and application thereof, and belongs to the technical field of biotechnology. The method comprises the following steps: mixing Gracilaria lemaneiformis powder with water, performing ultrasonic cell wall disruption and hot water extraction, and obtaining a crude polysaccharide extract; adding cellulase and vitamin C to the crude polysaccharide extract, and performing synergistic degradation under ultrasonic conditions; after termination of the reaction, performing concentration, alcohol precipitation, gel column purification, dialysis and freeze-drying, and obtaining the degraded polysaccharide. The application firstly adopts ultrasonic assistance, cellulase and vitamin C to synergistically degrade Gracilaria lemaneiformis polysaccharide, and clearly shows that the degraded polysaccharide is composed of agarose typical structural units and red algal starch structural units. Animal experiments show that the degraded polysaccharide can significantly increase the total short-chain fatty acid content in the intestines of high-fat and high-sugar diet mice. The preparation method is mild, the structure is clear, the activity is significant, and the degraded polysaccharide can be applied to functional food or probiotic preparations for regulating intestinal flora and improving sugar and lipid metabolism.

The invention discloses an EETs metabolite kit, a detection method and application, and belongs to the technical field of biomedicine and nutrition metabolism. The kit internally comprises 14 (15)-EET, 11 (12)-EET, 8 (9)-EET and 14 (15)-EET-d11, the kit is subsequently detected by liquid chromatography-mass spectrometry, and the expression level standard of epoxy eicosatrienoic acid generated by metabolism of arachidonic acid (AA) through a CYP450 enzyme system is accurately obtained through the EETs metabolite kit and a liquid chromatography-mass spectrometry detection method; the effect of preventing, relieving and / or improving the intestinal injury caused by the high-glucose diet can be achieved by inhibiting high-level EETs metabolites in plasma of a patient suffering from the intestinal injury caused by the high-glucose diet.

The invention discloses application of rhizoma menispermi total alkaloids in preparation of a medicine for preventing and treating non-alcoholic fatty liver disease, and belongs to the technical field of biological medicine. Evaluation of the effect of the traditional Chinese medicine extract rhizoma menispermi total alkaloids on treatment of the non-alcoholic fatty liver disease shows that the extract can significantly reduce the body weight of high-fat and high-sugar diet obese mice, effectively improve the non-alcoholic fatty liver disease, effectively relieve liver fatty degeneration in vivo, reduce blood fat and improve liver functions, and can be used for treating the non-alcoholic fatty liver disease. The content of ALT, AST and TG in the blood of a mouse with obesity caused by high-fat and high-sugar diet is reduced, and the expression of inflammatory factors and hepatic fibrosis genes is inhibited at the same time. Therefore, the rhizoma menispermi total alkaloid can be used as a potential medicine for treating the non-alcoholic fatty liver disease.

The present invention relates to the field of biomedicine, and specifically provides an application of a selective TNFR1 antagonist peptide Hydrostatin-SN10 in the treatment of non-alcoholic fatty liver disease. The selective TNFR1 antagonist peptide Hydrostatin-SN10 has an amino acid sequence as shown in SEQ ID NO: 2. The present invention verified its selective binding to TNFR1 and its anti-inflammatory activity in vitro and in vivo through in vitro experiments. The results showed that Hydrostatin-SN10 may exhibit good anti-inflammatory activity by selectively binding to TNFR1 and inhibiting the interaction between TNF-α and TNFR1. By establishing an animal model of non-alcoholic fatty liver disease induced by a high-fat and high-sugar diet (HFD), it was demonstrated that Hydrostatin-SN10 has the use of treating non-alcoholic fatty liver disease.

The invention relates to a ginsenoside composition with an effect of regulating blood viscosity as well as a preparation method and application of the ginsenoside composition, and belongs to the technical field of biology. The invention provides a ginsenoside composition. The ginsenoside composition comprises at least two of ginsenoside Rc, ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rg6, ginsenoside F4, ginsenoside S-Rg3, ginsenoside R-Rg3, ginsenoside PPT, ginsenoside Rk1, ginsenoside Rg5 and ginsenoside Rh2. The ginsenoside composition provided by the invention has the efficacy of improving body weight rise, liver injury, lipid metabolism disorder, insulin level rise and oxidative stress caused by high-fat and high-sugar diet, and has the efficacy of improving blood viscosity rise, blood coagulation time reduction and blood coagulation factor level improvement caused by acute blood stasis; the effects of improving liver injury, blood fat, blood sugar and lipid metabolism disorder, regulating blood viscosity and resisting oxidation can be achieved, and the compound can be expected to be developed into an active raw material to be applied to the fields of biological medicine, cosmetics, food, health care products and the like.

The invention belongs to the technical field of resistant starch, and particularly relates to a Chinese yam starch-polyphenol nano-composite as well as a preparation method and application thereof. According to the preparation method provided by the invention, the gelatinized Chinese yam native starch and the polyphenol compound are compounded in ethanol under the condition of high-speed shearing to form the Chinese yam starch-polyphenol nano-composite with a V-shaped structure, a chemical cross-linking agent is not needed, and the process is simple, convenient, green and environment-friendly. The obtained compound has digestion resistance, has regulation activity on a glycolipid metabolism regulation function, has application potential of improving diet-induced obesity, and can also significantly improve glycolipid metabolism disorder induced by high-fat or high-glucose diet.

The invention discloses an application of purple bud tea in preparation of a medicine for improving metabolic disorders, belongs to the technical field of traditional Chinese medicines, and particularly relates to an application of purple bud tea, an extract of purple bud tea or a pharmaceutical composition of purple bud tea in preparation of a medicine for improving metabolic disorders. The purple bud tea extract disclosed by the invention can improve uric acid level rise caused by metabolic disorder, and has good prevention and treatment effects on metabolic disorder caused by sugar, fat and uric acid level rise caused by high-fat and high-sugar diet.

The invention discloses a construction method and application of a hepatolenticular degeneration damp-heat intrinsic mouse model, and relates to the technical field of biology. The method comprises the following steps: on the basis of Atp7b <- / -> mice, constructing by combining high-fat and high-sugar diet with high-temperature and high-humidity artificial climate box intervention. On the basis that HLD copper metabolism abnormity is reserved, syndrome changes conforming to the characteristic of damp-heat accumulation can be further induced. The model is systematically evaluated through indexes such as a general state, traditional Chinese medicine symptom integral, liver and jejunum histological change and an inflammatory factor level, so that the HLD damp-heat implication animal model with modern disease basis and traditional Chinese medicine syndrome characteristics is expected to be constructed, and an experimental basis is provided for mechanism research and traditional Chinese medicine intervention under the guidance of a traditional Chinese medicine'syndrome combination 'theory.